Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...

The COVID-19 pandemic highlighted the urgent need for effective therapeutic agents against SARS-CoV-2. Although vaccines helped control the spread of the virus, the emergence of new variants continues ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors.

Spike, in addition to being a transmembrane structural protein, is a class I fusion protein, whose function is to allow SARS-CoV-2 to enter its host cells. This glycoprotein is divided into two ...

The host protein fibrinogen has been found to interact with the N-terminal domain (NTD) of the spike protein in SARS-CoV-2. However, the evolutionary benefit of this binding to the virus still remains ...

ABSTRACT: SARS-CoV-2 poses a significant risk to global healthcare systems based on the recent worldwide COVID-19 pandemic. Spike proteins are the hallmark of SARS-Cov-2, which bind to ACE2 receptors ...

Kei Sato was looking for his next big challenge five years ago when it smacked him — and the world — in the face. The ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

Wildfire smoke exposure acutely increased IL-13 expression in NK cells and was negatively associated with COVID-19 vaccine immunity.

Richard Adeleke, a doctoral researcher at Cornell University, New York, USA, and his research group have developed a groundbreaking vaccine that could protect people from both COVID-19 and the flu in ...

and SARS-CoV-2. Non-human-pathogenic representatives included various Alphacoronaviruses, Betacoronaviruses, Gammacoronaviruses, and Deltacoronaviruses. These sequences were labeled as ...